These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19112310)

  • 1. Can troponin identify those critically ill septic patients who would benefit most from activated protein C treatment?
    Fernandes CJ
    Crit Care Med; 2009 Jan; 37(1):367-8. PubMed ID: 19112310
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach.
    Weintraub J; Satterwhite T; Allo M
    Burns; 2006 Sep; 32(6):783-7. PubMed ID: 16879921
    [No Abstract]   [Full Text] [Related]  

  • 3. [Coagulation tests during treatment with Drotrecogin alpha (activated): do results reflect the clinical situation?].
    Roca de Togores López A; Armero Ibáñez R; Seller Losada JM; Petusa Collado V; Onrubia Fuertes X; Sifre Julio C; Bellver Romero J; Barberá Alacreu M
    Rev Esp Anestesiol Reanim; 2005 Feb; 52(2):117-8. PubMed ID: 15765996
    [No Abstract]   [Full Text] [Related]  

  • 4. Activated protein C (Xigris): a drug in trouble.
    Vangerow B; Mignini MA
    Acta Anaesthesiol Scand; 2007 Feb; 51(2):261-2. PubMed ID: 17261152
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of severe sepsis and septic shock in critically ill patients.
    Namendys-Silva SA; Hernández-Garay M
    Heart Lung; 2012; 41(4):408-9. PubMed ID: 22534210
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

  • 8. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 9. Using transcutaneous oxygen pressure measurements as selection criteria for activated protein C use.
    Chapital AD; Yu M; Ho HC; Wang J; Koss W; Takanishi DM
    J Trauma; 2008 Jul; 65(1):30-3. PubMed ID: 18580526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
    Levi M
    Crit Care Med; 2003 Mar; 31(3):984-5. PubMed ID: 12627023
    [No Abstract]   [Full Text] [Related]  

  • 11. Criteria for use of drotrecogin alfa.
    Mann HJ
    Am J Health Syst Pharm; 2004 Jan; 61(2):202; author reply 204-5. PubMed ID: 14750406
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sepsis in the surgical setting: indication for activated C protein].
    Payen DM; Matéo J
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():40-2. PubMed ID: 15359942
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of severe sepsis and multiple organ failure with activated protein C].
    Strøm JJ
    Ugeskr Laeger; 2004 Mar; 166(11):995. PubMed ID: 15049233
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting the coagulation cascade in sepsis: did we find the "magic bullet"?
    Mathiak G; Neville LF; Grass G
    Crit Care Med; 2003 Jan; 31(1):310-1. PubMed ID: 12545036
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 16. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 17. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 18. Activated protein C for sepsis.
    Mackenzie A
    N Engl J Med; 2010 Mar; 362(12):1150-1; author reply 1151. PubMed ID: 20335597
    [No Abstract]   [Full Text] [Related]  

  • 19. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical experience with xigris].
    Wyncoll D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():46-7. PubMed ID: 15359944
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.